Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) fell 0.5% during trading on Tuesday . The company traded as low as $1.8077 and last traded at $1.81. 4,444 shares traded hands during trading, a decline of 83% from the average session volume of 26,053 shares. The stock had previously closed at $1.82.
Analyst Ratings Changes
A number of brokerages recently weighed in on IPHA. Leerink Partnrs cut Innate Pharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Innate Pharma in a report on Wednesday, October 8th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective (down from $10.00) on shares of Innate Pharma in a research note on Thursday, September 18th. HC Wainwright set a $5.00 target price on Innate Pharma and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of Innate Pharma in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Innate Pharma has a consensus rating of “Hold” and an average target price of $5.00.
View Our Latest Analysis on IPHA
Innate Pharma Stock Down 0.5%
Innate Pharma Company Profile
Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.
The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.
Featured Stories
- Five stocks we like better than Innate Pharma
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
